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Abstract
During the last decade, the epidemiology of WNV in humans has changed in the southern regions of Europe, with high
incidence of West Nile fever (WNF) cases, but also of West Nile neuroinvasive disease (WNND). The lack of human vaccine or
specific treatment against WNV infection imparts a pressing need to characterize indicators associated with neurological
involvement. By its intimacy with central nervous system (CNS) structures, modifications in the cerebrospinal fluid (CSF)
composition could accurately reflect CNS pathological process. Until now, few studies investigated the association between
imbalance of CSF elements and severity of WNV infection. The aim of the present study was to apply the iTRAQ technology
in order to identify the CSF proteins whose abundances are modified in patients with WNND. Forty-seven proteins were
found modified in the CSF of WNND patients as compared to control groups, and most of them are reported for the first
time in the context of WNND. On the basis of their known biological functions, several of these proteins were associated
with inflammatory response. Among them, Defensin-1 alpha (DEFA1), a protein reported with anti-viral effects, presented
the highest increasing fold-change (FC.12). The augmentation of DEFA1 abundance in patients with WNND was confirmed
at the CSF, but also in serum, compared to the control individual groups. Furthermore, the DEFA1 serum level was
significantly elevated in WNND patients compared to subjects diagnosed for WNF. The present study provided the first
insight into the potential CSF biomarkers associated with WNV neuroinvasion. Further investigation in larger cohorts with
kinetic sampling could determine the usefulness of measuring DEFA1 as diagnostic or prognostic biomarker of detrimental
WNND evolution.
Citation: Fraisier C, Papa A, Granjeaud S, Hintzen R, Martina B, et al. (2014) Cerebrospinal Fluid Biomarker Candidates Associated with Human WNV Neuroinvasive
Disease. PLoS ONE 9(4): e93637. doi:10.1371/journal.pone.0093637
Editor: Tian Wang, University of Texas Medical Branch, United States of America
Received November 18, 2013; Accepted March 5, 2014; Published April 2, 2014
Copyright:  2014 Fraisier et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007 - 2 013) under
the project ‘‘VECTORIE’’, EC grant agreement number 261466. This study was also supported by De´le´gation Ge´ne´rale pour l’Armement (DGA, ArthroSer 10Ca 401).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: almeras.lionel@gmail.com
Introduction
West Nile virus (WNV) belongs to the Flaviviridae family (genus
Flavivirus), transmitted to humans by the bite of infectious
mosquitoes, mainly from the Culex genus [1]. In nature, avian
hosts are the main reservoir of WNV; nevertheless transmission to
other vertebrates can occur [2]. Humans and equines are sensitive
to WNV infection, but they are considered as incidental dead-end
hosts, due to the low and short viremia [3].While the majority of
humans infected with WNV remain asymptomatic, approximately
20% develop a transient febrile illness, known as West Nile fever
(WNF); and about 1% of infected individuals develop a
neuroinvasive disease (WNND) characterized by encephalitis,
meningitis, and/or acute flaccid paralysis, leading in some cases to
a fatal outcome [4,5].
During the last decade, the epidemiology of WNV has changed
in the more southern regions of Europe, with increased incidence
of WNND in humans [6]. Unexpectedly in 2010, the first large
outbreak of WNV infections occurred in Greece [7]; it was
characterized by the census of nearly 200 WNND cases with 17%
fatality rate [8]. Since then, the reports of WNV outbreaks are
increasing. A recent update on the Italian epidemic between 2008
and 2011, reported 43 cases of WNND with 16% fatality rate [9],
while in Balkans several WNND cases have been reported
[10,11,12]. The recent epidemiologic studies underline that in
Europe, like in the United States, WNV infections, and
particularly WNND cases, have become of major public health
concern [13]. Despite the development of successful WNV
vaccines for equines and the ongoing clinical trials for human -
vaccines, no licensed vaccine for human use is currently available
[5]. Antibody therapy (i.e., WNV-specific immunoglobulins)
[14,15], ribavirin [16,17] and treatment with interferon-a
[18,19] showed therapeutic potential for clinical use in humans,
but larger clinical trials are required to establish their therapeutic
efficacy. Thus, currently no specific antiviral treatment for WNV
infections is available and only supportive care is administered.
Although the management of WNV infection has progressed by
the development of molecular and serological tools for laboratory
diagnosis [5,20], early clinical diagnosis is still challenging because
the initial symptoms are not specific. The prediction of clinical
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evolution to either recovery or central nervous system (CNS)
involvement has not been yet elucidated. Thus, the identification
of biomarkers associated with disease severity could enable a better
forecasting of WNV disease progression (i.e., distinction between
WNND and WNF) and could improve knowledge of brain
alteration to define novel potential drug targets.
The CNS is separated from the rest of the body by blood
interfaces, which are mainly composed of the blood-brain barrier
(BBB) and the blood-cerebrospinal fluid (CSF) barrier, which
maintain the CNS homeostasis, and preserve it from toxic
compounds or pathogens. However several neurotropic viruses,
such as WNV, can bypass BBB and invade the CNS [21,22]. By its
close contact with the extracellular fluid of the brain, analysis of
CSF composition can reflect biological CNS impairments enabling
the diagnosis and understanding of various neurodegenerative
CNS disorders [23]. The presence of WNV-specific IgM
antibodies in the CSF is a strong evidence of a recent infection,
however, neutralization assays or detection of WNV RNA could
be necessary in case of suspicion infection with other flaviviruses
due to cross-reactivity [24]. Furthermore, the persistence of WNV
IgM antibodies in CSF for several months after the onset of the
disease complicates the laboratory diagnosis [25]. Thus, these
biological tests could reflect neurological infection, but not direct
relationship with acute encephalitis.
The number of studies which analyze the CSF component
modifications during WNV infection, or investigate the association
between imbalance of CSF elements and severity of WNV
infection is very limited. Some reports postulated that the number
of plasma white cells in CSF could be used as an indicator of brain
WNV infection [26,27], but these findings were not confirmed by
more recent studies [28,29], suggesting that the predictive value
for WNND diagnosis is low. Recently, Petzold and collaborators
observed that the CSF levels of neuronal (i.e., neurofilaments) and
glial (i.e., glial fibrillary acidic protein (GFAP) and S100B)
biomarkers were elevated in WNV encephalitis patients compared
to non-inflammatory controls [30]. Nevertheless, these biomarkers
were also detected in CSF and sera from WNF patients,
reconsidering the use of these proteins as prognostic markers of
disease severity [30,31]. The biological content of the CSF has
long been used as an indicator regarding diagnoses or etiology of
CNS-related symptoms and dysfunctions [32,33]. Thus, to
monitor biological effects of CNS infections, proteomic investiga-
tions of CSF have produced quite promising results in the
discovery of biomarkers associated with brain infection [34,35].
To gain a better insight into the pathophysiology of severe
WNV infection in humans and to identify potential biomarkers
associated with neuroinvasion, a comparative examination of CSF
protein profiles between patients with WNND and control
individuals with non-inflammatory symptoms was performed
using a quantitative proteomic approach (iTRAQ).
Materials and Methods
Ethics statement
The Medical Ethical Committees of the Erasmus University
Medical Centre in Rotterdam, The Netherlands, the Sint
Franciscus Gasthuis in Rotterdam, The Netherlands, and the
Medical Ethical Committee of Aristotle University of Thessaloniki,
Greece, approved the study protocol. Serum and CSF samples
used for the ELISA validation tests were both previously banked
de-identified samples collected for diagnostics, or from individuals
living in Marseille, France, from whom a written informed consent
was obtained, and the Marseille-2 Ethical Committee approved
the protocol.
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Material
All subjects included in the present study were Caucasians.
Demographic and clinical data relating to these individuals are
detailed in the Table 1. They were divided into the following
groups:
A. The WNND group, consisted in total of 51 Greek patients
(25 females). This group included the subgroup A1 (n = 16) for
whom both serum and CSF samples were available; the subgroup
A2 (n = 8) for whom only a CSF sample was available; and the
subgroup A3, (n = 27) for whom only a serum sample was
available.
B. The WNF group, named B1, consisting of 23 Greek patients
with WNF for whom only a serum sample was available.
C. The control groups, consisting of the following sub-groups:
C1 group, consisting of 13 Greek patients with non-WNV CNS
infection for whom paired serum and CSF was available; C2
group, consisting of 6 Dutch individuals with acute headache (AH
group), for whom only a CSF sample was available; C3 group,
including 5 Dutch female individuals with idiopathic intracranial
hypertension (IIH group), for whom only a CSF sample was
available; and C4 group, consisting of 21 apparently healthy
French individuals (‘‘healthy group’’). The 11 individuals from the
AH and IIH groups had no neurological disorders, did not take
any medication, and were considered to have normal CSF.
Protein sample preparation
Due to the limited volume of the CSF samples, pooled CSF
samples from each experimental group (i.e., A2, C2 and C3
groups) were generated by mixing an equal volume (30 mL) of each
sample per group. The protein concentration of each sample pool
was determined by the Lowry method (DC Protein assay Kit, Bio-
Rad) according to the manufacturer’s instructions. The WNND
group (A2 group) had higher CSF protein concentration (mean:
907 mg/mL) than the AH (mean: 479 mg/mL, C2 group) and IIH
(mean: 249 mg/mL, C3 group) control groups. Each pool was
vortexed for 30 seconds and then subdivided into vials containing
30 mg protein stored at 280uC until further use.
iTRAQ labeling of CSF samples
iTRAQ is a gel-free based technique to quantify proteins from
different sources in a single experiment. This technique incorpo-
rates covalently isobaric tags to enable quantitative proteomic
analysis [36]. For iTRAQ labeling, replicates of CSF sample pools
containing 30 mg protein were used (Table S1). Proteins were
precipitated with cold acetone for 2 h at –20uC, centrifuged for
5 min at 16 0006g, dissolved in 20 mL of dissolution buffer,
denatured, reduced, alkylated and digested with 10 mg of trypsin
overnight at 37uC, following manufacturer’s protocol (iTRAQ
Reagent Multiplex Buffer kit, Applied Biosystems, Foster City,
CA, USA) and as previously described [37]. The resulting peptides
were labeled with iTRAQ reagents (iTRAQ Reagent-8Plex
multiplex kit, Applied Biosystems) according to manufacturer’s
instructions. Before combining the samples, a pre-mix containing
an aliquot of each labeled sample, cleaned-up using a ZipTip, was
analyzed by MS/MS to check for peptide labeling efficiency with
iTRAQ reagents and homogeneity of labeling between each
sample. The content of each iTRAQ reagent-labeled sample was
then pooled into one tube according to this previous test. The
mixture was then cleaned-up using an exchange chromatography
(SCX/ICAT cation exchange cartridge, AB Sciex, Foster City,
USA) and reverse-phase chromatography C18 cartridge (C18
SpinTips, Protea bio, Nıˆmes, France) prior to separation using an
off-gel system (Agilent 3100 OFFGEL fractionator, Agilent
Technologies), as previously described [38].
Mass spectrometry analysis
For nanoLC mass spectrometry (MS) measurements, approxi-
mately 5 mg of peptide sample was injected onto a nanoliquid
chromatography system (UltiMate 3000 Rapid Separation LC
(RSLC) systems,Dionex, Sunnyvale, CA). After pre-concentration
and washing of the sample on a Dionex Acclaim PepMap 100 C18
column (2 cm6100 mm internal diameter (id) 100 A, 5 mm
particle size), peptides were separated on a Dionex Acclaim
PepMap RSLC C18 column (15 cm675 mm id, 100 A, 2 mm
particle size) (Dionex, Amsterdam) using a linear 180 min gradient
(4-40% acetonitrile/H20; 0.1% formic acid) at a flow rate of
300 nL/min. The separation of the peptides was monitored by a
UV detector (absorption at 214 nm). The nanoLC was coupled to
a nanospray source of a linear ion trap Orbitrap mass
spectrometer (LTQ VelosOrbitrap, Thermo Electron, Bremen,
Germany). The LTQ spray voltage was 1.4 kV and the capillary
temperature was set at 275uC. All samples were measured in a
data dependent acquisition mode. Each run was preceded by a
blank MS run in order to monitor system background. The
peptide masses were measured in a survey full scan (scan range
300–1700 m/z, with 30 K FWHM resolution at m/z = 400, target
AGC value of 106 ions and maximum injection time of 500 ms). In
parallel to the high-resolution full scan in the Orbitrap, the data-
dependent HCD scans of the 10 most intense precursor ions were
fragmented and measured in the orbitrap analyser (normalized
collision energy of 35%, activation time of 10 ms target AGC
value of 104, maximum injection time 100 ms, isolation window
2 Da and wideband activation enabled). Dynamic exclusion was
implemented with a repeat count of 1 and exclusion duration of
30 sec.
Data Analysis
Raw files generated from MS analysis were combined and
processed with Proteome Discoverer v 1.3 (Thermo Fisher
Scientific, Waltham, MA, USA). Protein identification and
quantification were carried out using the Mascot search engine
(v.2.3; Matrix Science, Boston, MA, USA) and SEQUEST
(v.28.0.0.0; University of Washington) through Proteome Discov-
erer v 1.3 (Thermo Scientific). The search was performed against
the Homo Sapiens Sapiens database containing 20257 sequences
(from SwissProt, May 24rd, 2012). Data were processed as
described previously [39]. Several comparisons were performed
including WNND group (A2 group) vs AH+IIH group (C2+C3
groups), but also WNND (A2 group) vs AH (C2 group) or vs IIH
(C3 group) groups. Conversely, the proteins differentially ex-
pressed between AH (C2 group) and IIH (C3 group) groups were
excluded from the analysis to take into account only the protein
abundance specifically altered in WNND samples. Proteins whose
expression were significantly differentially expressed (|fold-
change|$2, p-value#0.05) were selected for the analysis. Change
in protein expression (between two groups) is reported as ratio or
as fold-change (FC). Fold-change equals ratio when ratio is larger
than 1; FC equals minus one over ratio when ratio is lower than 1.
Ingenuity pathway analysis
The functional analyses were generated through the use of
Ingenuity Pathways Analysis software, Inc. (http://www.
ingenuity.com). In this analysis, the average relative proteins
expression values (fold-change) obtained from MS analysis were
uploaded into the IPA software. The IPA program uses a
knowledgebase (IPA KB) derived from the scientific literature to
connect genes or proteins based on their relationships and
functions. IPA generates biological networks, canonical pathways
and functions that are relevant to the uploaded dataset. A right-
CSF Biomarkers Associated with WNV Neuroinvasion
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tailed Fisher’s exact test is used for calculating p-values to
determine if the probability that the association between the
proteins in the dataset and the functional and canonical pathway
can be explained by chance alone. The scores derived from a p-
value (score = -log (p-value)) and indicated the likelihood that the
proteins of interest (i.e., the identified proteins within a network)
were clustered together.
ELISAs
Defensin alpha-1 (DEFA1) concentration was evaluated in
paired CSF and serum (A1 and C1 groups) or only in serum
samples from individuals of the different clinical groups (A3, B1
and C3 groups) by capture enzyme-linked immunosorbent assay
(ELISA) kits according to the manufacturer’s instructions (Uscn,
Life Science Inc., Wuhan, China). Plates were read in an ELISA
microplate reader (Versa Max TurnableMultiplate Reader,
Molecular Devices, UK). Paired CSF/serum samples from the
same individual were tested on the same plate in duplicate.
Statistical analysis
Since values in each group did not follow a Gaussian
distribution or sample size is too small, we used non-parametric
tests. The Kruskal-Wallis test was used for multiple group
comparisons. Two independent groups were compared with
Mann-Whitney U test. Spearman’s rank correlation coefficient
was computed when appropriate. Threshold values were deter-
mined with the use of receiver operating characteristic (ROC)
curve. All differences were considered significant at p,0.05 and
statistical analyses were performed using the statistical software
Prism 5 (GraphPad, Inc).
Results
Differential expression of CSF proteins between WNND
patients and non-infected individuals
CSF samples were tested for the identification of differentially
expressed proteins between WNND patients (i.e., A2 group) and
the control groups (i.e., C2 and C3 groups), using iTRAQ labeling
and MS analysis. The application of a global False Discovery Rate
(FDR) of 5% gave rise to a total of 470 identified and quantified
proteins that were included in the analysis.
The comparison of protein abundance variations between the
AH- and IIH-control groups indicated that 11 proteins were
significantly differentially expressed (average ratios#0.5 or $2, p-
value#0.05; Table 2): six proteins were up-regulated (fold-change
(FC) ranging from 2.1 to 3.5), including four proteins from the
apoliprotein family (APOC1, APOB, APOL1, APOM), involved
in lipoprotein particle composition responsible for lipid trafficking
and metabolism, and five proteins, all belonged to the keratin
protein family, were down-regulated (FC ranging from 28.8 to
22.0) (Table 2). Since these keratin proteins are mainly structural
constituents of epidermis, it is possible that their up-representation
in the IIH-group could result from a contamination associated
with CSF sampling and handling. Thus, the protein changes
concerned mainly two protein family groups, which could be
attributed to sample contamination or abundance of lipoprotein
particles.
The comparison of protein abundance variations between
WNND and the AH+IIH control groups highlighted 51 proteins
that were found significantly differentially expressed (Figure 1A).
Among them, 47 proteins modified exclusively in patients with
WNND compared to AH+IIH group were taken into account
(Figure 1B, Table 3). The large majority of these proteins were up-
regulated (42 and five proteins up- and down-regulated, respec-
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tively), and fold-changes were much higher for up- (ranging from
2.0 to 12.9) than for down-regulated proteins (ranging from 22.0
to 22.2). Interestingly, 32 out of the 47 differentially expressed
proteins were found commonly modified considering WNND vs
AH and WNND vs IIH comparisons (Figure 1B, Table 3). The 47
significantly differentially expressed proteins were classified
according to their cellular distribution and were grouped into
functional categories according to gene ontology (GO) (Figure 1C
and 1D), using Proteome Discoverer software 1.3 (Therome
scientific) retrieving GO database information from ProteinCenter
software (Thermo Scientific). As expected, a large majority of them
(62%) was secreted (biological fluid) and the first functional
category corresponded to immune response (47%). Among the
proteins from the immune response, half of them corresponded to
immunoglobulin chains (n = 10) which reflected the absence of
immunoglobulin depletion prior the quantitative protein reper-
toire analysis, but also indicated the inflammatory phenomenon
which occurred in the WNND group compared to control group.
Protein networks and biological functions altered in the
CSF of WNND patients
To determine significant networks and biological functions
associated with human WNND cases, the 47 differentially
expressed proteins identified in CSF were uploaded into the IPA
system. Among them, 41 proteins were mapped in the system
(Table 3). The functional analyses generated through the IPA
system identified direct and indirect relationships among the
proteins differentially expressed and allowed to identify two
relevant networks (Table 4). These networks contained at least
15 focus molecules involved in functions related mainly to
inflammatory and immunological diseases. In addition, among
the biological functions related to these proteins, 15 differentially
expressed proteins (DEFA1, S100A9, LCN2, S100A8, IGHM,
HIST1H2BK, IGJ, PRDX2, ACTB, FGA, CD14, HP, FCGR3A,
TIMP1, APOE), classified in infectious disease, were significantly
associated with viral infection (p-value: 2.58E-05). With the
exception of APOE, all these proteins were up-regulated.
Verification by ELISA of the selected candidate, DEFA1
Defensin alpha-1 (DEFA1) abundance in biological fluids (i.e.,
CSF and serum) was assessed using commercial ELISA kits.
Selection of DEFA1 was made on the basis of its high fold-change,
the possible functional association of this protein with WNV
pathobiology or the potential use as severe infection biomarker,
and the availability of the required ELISA kits.
Due to their insufficient remaining volume, CSF samples from
individuals previously used for the proteome repertoire compar-
isons could not be further assessed by ELISA (i.e., A2, C2 and C3
groups). Thus, the validation tests were carried out on the WNND
group (n = 16, A1 group) and the non-WNV CNS infection
control group (n = 13, C1 group). Additionally to the validation of
the protein abundance variations observed at the central level
(i.e.,CSF), counterpart sera collected at the same time point were
used to determine whether the selected differentially expressed
protein could also be detected at the peripheral level (i.e.,serum). In
the case of this protein would be specifically associated with
neurological symptoms of WNV infection, its detection at the
peripheral level could be useful and much easier for the physicians
to follow and predict risk of WNV severe/detrimental evolution.
DEFA1 showed a significant increase of protein abundance in
both CSF (p,0.02, Mann-Whitney U test) and sera (p,0.003,
Mann-Whitney U test) from WNND patients compared to control
subjects (Figure 2A and 2B). The concentration of DEFA1 in CSF
(mean 6 SD: 43.84676.70 ng/mL) and serum (1.12660.812 mg
/mL) from WNND patients were found with a 6.1- and a 3.4-fold
increase, respectively, than that detected in CSF (7.12614.73 ng/
mL) and serum (0.40360.590 mg/mL) from control subjects. The
CSF proteomic analysis indicated that DEFA1 was approximately
12 times more abundant in the WNND group compared to the
AH+IIH group (Table 3), which is consistent with the DEFA1
ELISA test validation. Interestingly, a significant positive correla-
tion coefficient (rho.0.76, p,0.001, Spearman’s rank test) was
obtained for the concentration of DEFA1 between sera and CSF
from WNND patients (Figure 2C). The high levels of DEFA1 in
sera from WNND group, more than 25-fold compared to
counterpart CSF, led to a best-fit line running below the diagonal
(slope: 0.064360.0183).
Comparison by ELISA of serological DEFA1 levels
between WNND patients, WNF patients and healthy
controls
Finally, to assess the potential use of this protein to distinct
severity of the WNV infections, the abundance of DEFA1 was
measured by ELISA in serum samples from a third group of
WNND patients (i.e., A3 group), compared to WNF patients (i.e.,
B1 group) and healthy controls (i.e., C4 group). A significant
difference was observed between the three groups (p,0.008,
Kruskal-Wallis test). The level of DEFA1 was found significantly
more elevated in the group of WNND patients (mean 6 SD:
1.01361.048 mg/mL) compared to the group of WNF patients
(mean 6 SD: 0.50360.287 mg/mL, p,0.05, Mann-Whitney U
test) and to the group of healthy individuals (mean 6 SD:
0.38860.196 mg/mL, p,0.003, Mann-Whitney U test). In
contrast, despite a higher level of DEFA1 in the group of WNF
patients compared to the group of healthy individuals, no
significant difference could be detected (p.0.05, Mann-Whitney
U test). The application of a ROC curve allowed defining the
threshold value to distinguish WNND from WNF patients at the
serum level (0.668 mg/mL). Using this DEFA1 threshold value, a
sensitivity and specificity of 55.6% and 78.3% at the serum level
were obtained, respectively.
Discussion
The recent increasing number of WNND cases reported in
Europe, the incomplete understanding of the factor(s) underlying
neurological symptoms, and the lack of human vaccine or specific
treatments against WNV infection impart a pressing need to
characterize indicators associated with these neurological cases.
Until now, no biologic marker (no laboratory marker) is available
to predict the progression to WNND or to distinguish between
WNF and WNND, creating diagnosis dilemmas and impeding
research into understanding the pathogenesis of the disease. By its
intimacy with CNS structures, any changes in the CSF compo-
sition could accurately reflect CNS pathological processes offering
a unique window to study CNS disorders. Despite the importance
of WNV as a CNS pathogen, there is no detailed study of CSF
protein variation contents in WNND patients. Thus, the present
study was conducted to investigate differences in the CSF
proteome between WNND patients (i.e., A2 group) and individuals
with non-infectious illness (i.e., C2 and C3 groups), using the
iTRAQ technology. Forty-seven proteins were found exclusively
modified in the CSF of WNND patients as compared to these
control groups. On the basis of their known biological functions, a
majority of these proteins, which are reported for the first time in
WNND patients, can be associated with neurological inflamma-
tion. Some of them were proposed as potential prognostic
CSF Biomarkers Associated with WNV Neuroinvasion
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biological markers of detrimental disease evolution/disease sever-
ity.
Among the proteins found differentially modified, 22 were
classified as related to immune response with half of them
corresponding to immunoglobulin chains (n = 10). The detection
of immunoglobulin chains was expected because it is well known
that an antibody response was elicited following WNV infection
which is responsible for the clearing of the virus [40]. The presence
of specific IgM antibodies against WNV antigens in CSF is
currently used as diagnostic criteria of neurological involvement
[5]. However, since anti-WNV IgM could persist in CSF during
several months [25], and since cross-recognition with related
flaviviruses could occur, other criteria should be taken into
account for a definitive diagnosis [5]. Interestingly, as anti-WNV
IgG have been reported to be detectable 8 days after the onset of
symptoms, and since the mean time of sample collection for the
WNND group was less than 7 days after illness onset, it is not
surprising to identify mainly alpha (IgA) or mu (IgM) immuno-
globulin heavy chains, which were found up-regulated, and
reported to generally appear between 4–7 days after WNV
exposure [41]. Anti-WNV IgA has been already evoked as a
marker of WNV infection in CSF [42], but like anti-WNV IgM,
these immunoglobulins are still detectable several months after the
WNV infection [43]. Nevertheless, the up-regulation of IgM and
IgA immunoglobulin heavy chains at the early stage following
WNV infection, confirmed the local production of antibodies.
Additionally, immunoglobulins are one of the most abundant
proteins in CSF. These proteins, together with other high
abundant proteins (e.g., albumin), are generally eliminated from
CSF samples for proteomic analysis to reduce protein masking,
allowing to increase the efficiency of low abundant protein
identification [44].
A hallmark of the present study is that, at the exception of the
presynaptic Neurexin-3-alpha and the floor plate-secreted Spon-
Figure 1. Classification of human CSF proteins significantly differentially expressed between WNND patients (i.e., A2 group) and
control individuals (i.e., C2 and C3 groups) identified by quantitative LC-MS/MS analysis. (A) The number of proteins significantly
differentially expressed between WNND group and AH+IIH control group or between AH and IIH control sub-groups are represented in the Venn
diagram. (B) Venn diagram representation of proteins significantly differentially expressed between WNND group and AH or IIH control sub-groups,
among the proteins found deregulated exclusively in patients with WNND compared to AH+IIH group (n = 47). The two groups that were compared
are indicated below each circle. The number and the percentage of proteins associated with each category are indicated in brackets. Classification of
the significantly differentially regulated proteins according to their sub-cellular location (C) and their functional categorization (D) according to gene
ontology (GO). The percentages of proteins associated with each category are indicated. WNND, West Nile neuroinvasive disease; AH, acute
headache; IIH, idiopathic intracranial hypertension; CSF, cerebrospinal fluid.
doi:10.1371/journal.pone.0093637.g001
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din-1, no other brain- or nervous system-specific proteins were
found modified in WNND patients. As the aim of the present work
was the characterization of potential biological marker(s) which
could be further used for the diagnosis of WNND, or for the
prediction of the risk to develop these severe neurological
symptoms, the identification of brain-specific proteins correspond-
ing to a neuronal damage was one of our expectations. It is
probable that some proteins with weak expression level could not
be detected in the present study due to the non-depletion of high
abundant proteins, and then their variations in protein abundance
were not considered. For example, the glial (i.e., GFAP and S100B)
and neuronal (i.e., neurofilaments) proteins, previously detected
with increased amount in CSF from WNV encephalitis patients
could not be confirmed here [30].
Among the modified proteins, DEFA1 was the CSF protein
with the highest abundance increase in WNND patients compared
to control groups, with a FC higher than 12 (FC = +12.894). The
increase of DEFA1 was even nearly twice more important than
that observed for the protein showing the second highest variation
(i.e., Hemoglobin subunit beta, FC = +6.671). DEFA1 is a peptide
composed of 30 amino acids (3.5 kDa) secreted mainly by
neutrophils [45,46]. Although a-defensins were initially identified
for their antimicrobial activity, these small peptides were shown to
be also active against a wide range of fungi, parasites and viruses
[47,48]. Effectively, it has been demonstrated that DEFA1 could
protect against infection with some enveloped virus (i.e., CMV,
HSV, influenza virus) [49]. Although the precise anti-viral effect of
DEFA1 is still unresolved, an inhibition of viral protein synthesis
was reported [50]. To our knowledge, it is the first time that this
peptide is evoked in WNV infection and its high abundance
increase in WNND CSF could reflect a strong host response
contributing to virus infection reduction. The up-regulation of
DEFA1 was validated by ELISA at both CSF and serum levels
using paired CSF/serum samples from another group of WNND
patients (i.e., A1 group), as compared to controls (i.e., C1 group).
Although the concentration of DEFA1 was 25 times more elevated
in sera than in CSF of WNND patients, a positive significant
correlation was observed between the two biological fluids. The
detection of high serum DEFA1 concentration, more likely
suggests a production of this protein at the peripheral level rather
than a leak from the CSF to serum following a BBB disruption.
Interestingly, it is not uncommon to detect increased number of
neutrophils in the CSF of WNND cases [27,51], suggesting that
DEFA1 detected in CSF could result from a release of CSF
neutrophils. It will be, thus, interesting to determine whether there
is a relationship between DEFA1 abundance and CSF neutrophils
count in the CSF, and to investigate the role of DEFA1 in the
WNND physiopathology. Nevertheless, based on the present
results, it could not be excluded that the CSF DEFA1 was
produced by local neutrophils or from production in serum.
Moreover, a confirmation of significant higher serum DEFA1
levels was noticed using another group of WNND patients (i.e., A3
group) compared to healthy individuals (i.e., C4 group) but also to
WNF patients (i.e., B1 group). The higher abundance of DEFA1 at
the peripheral level in WNND patients compared to those with
WNF, suggests that this peptide could serve as potential biologic
marker of WNV neuroinvasion. Nevertheless, the specificity of this
assay should be confirmed in larger cohorts of WNND and WNF
patients in a blind study. Additionally, cross checking experiments
in CSF and/or serum samples from patients infected with other
neurotropic viruses (e.g., herpesviruses, enteroviruses) are needed
to determine whether the DEFA1 release is specific for WNV or it
is a common host response in viral CNS infections. However, the
confirmation of this assay to distinguish WNND from WNF cases
Table 4. IPA-generated networks of differentially expressed proteins identified by iTRAQ labeling between CSF samples from
WNND (i.e., A2 group) and AH- and IIH-control groups (i.e., C2 and C3 groups).
Top Functions Score Focus Molecules Molecules in Network
Inflammatory Disease, Connective Tissue
Disorders, Skeletal and Muscular Disorders
38 17 up-regulated
DEFA1 (includes others), FCGR3A, FGA, FGB, FGG, HP, LCN2, LYZ, MGP, PRTN3,
S100A8, S100A9, SERPINA3,
SIAE, TIMP1
down-regulated
APOE, CHGB
not in the dataset
Alpha catenin, chymotrypsin, Collagen(s), ERK1/2, Fibrin, Fibrinogen, HDL, Ige, IL1,
IL17R, Immunoglobulin, Integrin, Laminin, LDL, NADPH oxidase, Pro-inflammatory
Cytokine, Stat3-Stat3, trypsin
Immunological Disease, Hematological Disease,
Metabolic Disease
35 15 up-regulated
ACTB, CD14, CHI3L1, FCGBP, HBB, HBD, HIST1H4A (includes others), IGHA1, IGHM,
IGJ, LCP1, MSN, PDE8B,
PRDX2,
down-regulated
PIK3IP1,
not in the dataset
Akt, caspase, CD3, chemokine, ERK, F Actin, hemoglobin, Hsp70, Iga, IgG, Igm, IL12
(complex), Insulin, Mapk, NFkB (complex), P38 MAPK, PI3K (complex), Pkc(s), RNA
polymerase II, Vegf
AH : acute headache; IIH : idiopathic intracranial hypertension.
doi:10.1371/journal.pone.0093637.t004
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is the first demonstration of a laboratory biomarker which could
enable physicians to more rapidly diagnose patients with
neuroinvasive disease.
In silico analysis highlighted that 15 differentially expressed
proteins were significantly associated with viral infection. Among
them, LCN2, TIMP1, S100A8/9, and PRDX2 related to host
response and/or inflammation in neurological disorders, could be
used as potential biomarkers of brain pathology. Neutrophil
gelatinase-associated lipocalin (LCN2) is expressed in neutrophils
and is involved in innate immunity. LCN2 is expressed and
secreted under inflammatory conditions and up-regulates chemo-
kines expression in the CNS, particularly CXCL10 by astrocytes
[52]. Neurodegenerative diseases are characterized by a glial
reaction and LCN2 has been shown to be secreted by reactive
astrocytes as a neurotoxic mediator leading to neuron death [53].
LCN2 was also reported to be increased in CSF and plasma from
patients with multiple sclerosis [54]. The identification of LCN2
with an increased expression in the CSF from WNND patients
(FC.4.0) in the present study could be the result from its
expression in choroid plexus (CP)-infiltrating neutrophils during
the acute phase of inflammation, as previously described [55,56].
LCN2 could also bind the matrix metalloproteinase MMP9 to
stabilize its proteolytic activity and prevent its degradation [57].
MMPs are responsible of BBB disruption by degrading the
extracellular matrix, leading to cell invasion and cytokine
production [58]. In parallel, tissue inhibitors of metalloproteinases
(TIMPs) inhibit MMPs but paradoxically may also contribute to
the inflammatory process by keeping a balance between deposition
and degradation of extracellular proteins. This could be illustrated
by the increased levels of MMPs (including MMP9) and TIMP1 in
CSF from subjects with cerebral adrenoleukodystrophy (cALD)
which causes neuroinflammation and demyelination [59]. Inter-
estingly, TIMP1 was found to be increased in our study in WNND
patients [60], and could reflect brain damages following WNV
Figure 2. DEFA1 expression levels from patients with WNND, WNF and control groups. CSF (A) and serum (B) levels of DEFA1 measured
by ELISA between WNND patients (n = 16, A1 group) and subjects with non-WNV CNS infection (n = 13, C1 group). Each dot shows the mean DEFA1
concentration detected in serum from a single individual. Horizontal bars show medians. Data were compared using the non parametric Mann-
Whitney U test. (C) Correlation of DEFA1 levels between paired CSF and serum from WNND patients (n = 16, group A1). The data were analyzed using
Spearman’s rank correlation test with the best-fit line shown (black line). (D) Serum levels of DEFA1 measured by ELISA between WNND (n= 27, A3
group), WNF (n = 23, B1 group) patients and healthy individuals (n = 21, C4 group). Each dot shows the mean DEFA1 concentration detected in serum
from a single individual. Horizontal bars show medians. Data were compared using the non parametric Mann-Whitney U test. The dotted line
corresponds to the threshold value defined by ROC curve. WNND, West Nile neuroinvasive disease; WNF, West Nile fever; CNS, central nervous
system; CSF, cerebrospinal fluid; DEFA1, defensin-1 alpha.
doi:10.1371/journal.pone.0093637.g002
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neuroinvasion. The role of TIMP1 in neuroinflammation was
moreover supported by the gene up-regulation in Venezuelian
equine encephalitis virus (VEEV)-infected mouse brain [61].
Interestingly, two members of the S100 family proteins, S100A8
and S100A9, were both found up-regulated in patients with
WNND, with a FC.4.0. S100A8 and S100A9 proteins are
considered damage-associated molecular pattern molecules
(DAMPs) [62], constitutively expressed in neutrophils and
inducible in several inflammatory cells including macrophages
[63]. They are released in response to tissue injury and play an
important function in innate immunity by binding to Toll-Like
Receptor 4 (TLR-4) [64].
An increase abundance of PRDX2 was also detected in CSF
from WNND patients (FC.2.5). Peroxiredoxins have been
recently reviewed as biomarkers of oxidative stress [65], which is
considered one cause of pathogenic mechanisms in neurological
diseases. In particular, oxidation of PRDX2 was described to
occur in pathological situations and inflammation where neutro-
phils are activated [66]. PRDX2 has been reported contributing to
neuroprotection and was proposed for treatment for neurodegen-
erative diseases [67]. To our knowledge, this is the first time that
PRDX2 was reported in CSF from patients with viral neuroinva-
sive disease. Altogether, the elevated levels of PRDX2 and
S100A8/9 seem to indicate a host response to CNS infection in
WNND patients and further evaluation of these proteins as
relevant markers of severe WN disease would be needed.
Conclusion
The present study represents the first analysis of CSF proteome
from patients with WNND, enabling the identification of a list of
protein changes which can be helpful in the better understanding
of the WNV pathophysiology. Besides expected immunoglobulins,
several proteins were of particular interest as being associated with
host response and inflammation in neurological disorders. The
identification of potential biological biomarker(s), such as DEFA1,
could enable physicians to diagnose more rapidly the neurological
involvement. Furthermore, additional neutrophil-related proteins
(LCN2, TIMP1, S100A8/9, PRDX2) were found at higher levels
in CSF of WNND patients, underlining the likely key role played
by neutrophils in the development of the inflammatory response
and brain damage. Further investigation is warranted to determine
the usefulness of these proteins, like DEFA1, as a diagnostic tool
which can be followed-up in monitoring the patients with
neuroinvasive disease.
Supporting Information
Table S1 Experimental design for iTRAQ reagent-
labeling of CSF sample pools. Thirty microgram of each
pooled group; C2 group (pool-AH1 to AH3), C3 group (pool-IIH1
to IIH2) or WNND, A2 group (poolW1 to W3) were digested with
trypsin and the resulting peptides of each sample were specifically
labeled with one iTRAQ reagent as indicated below, previously to
mix all samples. WNND, West Nile neuroinvasive disease; AH,
acute headache; IIH, idiopathic intracranial hypertension; CSF,
cerebrospinal fluid.
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